Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Indini, Alice; Nigro, Olga; Lengyel, Csongor György; Ghidini, Michele; Petrillo, Angelica; Lopez, Salvatore; Raspagliesi, Francesco; Trapani, Dario; Khakoo, Shelize; Bogani, Giorgio

doi:10.3390/cancers13071663

Cited by 26 publications

(48 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovarian cancer is the fifth leading cause of death for women. In 2018, new cases of ovarian cancer diagnosis patients reached around 21,750 in the United States (US); an additional 13,940 deaths were also reported [40].…”

Section: Libs Analysis For Different Cancers Ovarian Cancermentioning

confidence: 99%

A Review on Laser-Induced Breakdown Spectroscopy in Different Cancers Diagnosis and Classification

et al. 2022

View full text Add to dashboard Cite

Due to the new demonstrations of Laser-induced breakdown spectroscopy (LIBS) applicability in a surprisingly wide variety of applications, the use of LIBS as a medical diagnostic tool is steadily gaining momentum. Especially in different cancer diseases, LIBS has the potential to become a fast and valuable analytical tool. We addressed LIBS equipment and quantitative analytical procedures, and signal enhancement techniques for improving element detection. For detailed aspects of applications, we reviewed the recent progress of LIBS in different cancer diseases diagnoses by using different tissues and medical fluid as samples. To fulfill the high demands in the medical industry and overcome the severe tissue sample problem, it is proposed that the chemometric and signal amplification techniques for quantitative analysis should be employed, and robust and effective LIBS devices should be developed. This overview of the different cancers by LIBS is meant to summarize the research performed to date and suggest some suitable advanced chemometrics techniques and effective LIBS devices, if successfully implemented, would be significantly beneficial to the medical field in the future.

show abstract

Section: Libs Analysis For Different Cancers Ovarian Cancermentioning

confidence: 99%

A Review on Laser-Induced Breakdown Spectroscopy in Different Cancers Diagnosis and Classification

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Women with platinum-resistant recurrent OC (ROC) continue to have a poor prognosis with limited treatment options. 2 3 Therefore, there is a clear unmet need to improve outcomes in this subset of patients.…”

Section: Introductionmentioning

confidence: 99%

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

Xia

Peng

Lou

et al. 2022

J Immunother Cancer

View full text Add to dashboard Cite

BackgroundCombination treatments with immune-checkpoint inhibitor and antiangiogenic therapy have the potential for synergistic activity through modulation of the microenvironment and represent a notable therapeutic strategy in recurrent ovarian cancer (ROC). We report the results of camrelizumab (an anti-programmed cell death protein-1 antibody) in combination with famitinib (a receptor tyrosine kinase inhibitor) for the treatment of platinum-resistant ROC from an open-label, multicenter, phase 2 basket trial.MethodsEligible patients with platinum-resistant ROC were enrolled to receive camrelizumab (200 mg every 3 weeks by intravenous infusion) and oral famitinib (20 mg once daily). All patients had disease progression during or <6 months after their most recent platinum-based chemotherapy. Primary endpoint was confirmed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1 based on investigator’s assessment. Secondary endpoints included disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), overall survival (OS), 12-month OS rate and safety profile.ResultsOf the 37 women enrolled, 11 (29.7%) patients had primary platinum resistant, 15 (40.5%) patients had secondary platinum resistant and 11 (29.7%) patients had primary platinum refractory disease. As the cut-off date of April 9, 2021, nine (24.3%) patients had achieved a confirmed objective response, the ORR was 24.3% (95% CI, 11.8 to 41.2) and the DCR was 54.1% (95% CI, 36.9 to 70.5). Patients with this combination regimen showed a median TTR of 2.1 months (range, 1.8–4.1) and a median DoR of 4.1 months (95% CI, 1.9 to 6.3). Median PFS was 4.1 months (95% CI, 2.1 to 5.7), and median OS was 18.9 months (95% CI, 10.8 to not reached), with the median follow-up duration of 22.0 months (range, 12.0–23.7). The estimated 12-month OS rate was 67.2% (95% CI, 49.4 to 79.9). The most common ≥grade 3 treatment-related adverse events were hypertension (32.4%), decreased neutrophil count (29.7%) and decreased platelet count (13.5%). One (2.7%) patient died of grade 5 hemorrhage that was judged possibly related to study treatment by investigator.ConclusionThe camrelizumab with famitinib combination appeared to show antitumor activity in heavily pretreated patients with platinum-resistant ROC with an acceptable safety profile. This combination might provide a novel alternative treatment strategy in platinum-resistant ROC setting and warranted further exploration.Trial registration numberNCT03827837.

show abstract

“…Immunotherapy can improve autoimmunity, and then effectively prevent and control the occurrence of OC (Rocconi et al, 2020). However, not all patients show the same degree of sensitivity to immunotherapy (Indini et al, 2021). Therefore, the study of the relationship between the immune microenvironment (TME) and the prognosis of OC at the molecular level is of great signi cance for screening the population with the best bene t from the immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

Identification of a Potential Alternative Splicing Prognostic Signature Associated With Immune Infiltrates of Ovarian Cancer

Han

Wang

2021

Preprint

View full text Add to dashboard Cite

Background: The mortality rate of ovarian cancer (OC) ranks the first in gynecological tumors, which seriously threatens women's health and life. In recent years, alternative splicing (AS) has gradually been considered to play a key role in immune infiltrates of tumor. However, the prognostic significance of AS events related to immune infiltrates in OC remains unknow. The aim of our research was to investigate the potential prognostic value of AS events associated with immune infiltrates in OC.Methods: The RNA sequences (RNA-seq) and clinical data were downloaded from the Cancer Genome Atlas (TCGA) database. The AS event data was obtained from TCGA SpliceSeq database. Single sample gene set enrichment analysis (ssGSEA) was performed to calculate the abundance of 28 immune cell types in samples from TCGA-OV dataset. A consensus clustering algorithm was used to group the OC patients. Differential expression analysis was used to identify differentially expressed AS events (DEASs) between groups. Univariate Cox regression analysis was implemented to screen for AS events with prognostic value. A least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox regression analyses was used to further narrow the AS events with prognostic value and construct an alternative splicing prognostic signature for predicting the prognosis of OC patients. Results: The OC patients from TCGA database were classified into two groups (cluster.A and cluster.B) based on the 28 types of TIIC using a consensus clustering algorithm. The patients in the cluster.A group had increased immune infiltrates compared with the cluster.B group. 3616 DEASs were acquired and 171 DEASs have prognostic value (p<0.05). 28 DEASs with prognostic value (p<0.001) were fitted into LASSO Cox regression and multivariate Cox regression analyses. A prognostic signature with 18 DEASs was constructed to predict the prognosis of OC patients. Each patient obtained a riskscore and the patients were classified into high-and low-risk group using the median riskscore as a cutoff. Kaplan-Meier curve revealed that the patients in high-risk group have poor outcome. Conclusions: Collectively, our research identified an alternative splicing prognostic signature associated with immune infiltrates of OC, which may provide new directions for the immunotherapy of OC patients.

show abstract

Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer

Cited by 26 publications

References 112 publications

A Review on Laser-Induced Breakdown Spectroscopy in Different Cancers Diagnosis and Classification

A Review on Laser-Induced Breakdown Spectroscopy in Different Cancers Diagnosis and Classification

Antitumor activity and safety of camrelizumab plus famitinib in patients with platinum-resistant recurrent ovarian cancer: results from an open-label, multicenter phase 2 basket study

Identification of a Potential Alternative Splicing Prognostic Signature Associated With Immune Infiltrates of Ovarian Cancer

Contact Info

Product

Resources

About